Switching or Simplifying Antiretroviral Therapy
10 questions
Learning Objectives
- Discuss the rationale for switching or simplifying antiretroviral therapy
- Describe common situations to consider for simplifying antiretroviral therapy
- Explain why some antiretroviral medications generally warrant a switch to a newer agent
- List the two-drug regimens that have been FDA-approved for maintenance antiretroviral therapy
- Summarize key findings with studies involving a switch to an integrase strand transfer inhibitor
Authors
Reviewers
3rd Edition
This is a substantial revision of the original Question Bank Topic. The previous edition was titled Switching or Simplifying Antiretroviral Therapy and available until September 1st, 2023.
CNE/CME Continuing Education
This question bank topic qualifies for:
View CE Notices
- 1 CME AMA PRA Category 1 Credit™, or
- 1 CNE contact hour (qualifies for pharmacology CE for advanced practice nurses)
CNE and CME Origination: June 1st, 2017
CNE and CME Reviewed: September 1st, 2023
CNE and CME Expiration: August 31st, 2026 (3rd Edition)
View CE Notices
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5
Print Certificate
Obtain proof of CE Explore this topic in detail in the Switching or Simplifying Antiretroviral Therapy Quick Reference,
or earn more CE for it in the Switching or Simplifying Antiretroviral Therapy Self-Study
or earn more CE for it in the Switching or Simplifying Antiretroviral Therapy Self-Study